Research programme: NRF2 antagonists - Vividion Therapeutics
Latest Information Update: 18 Aug 2021
At a glance
- Originator Vividion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action NF-E2-related factor 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer